Phase III Eribulin Trial Boosts OS in Liposarcoma Patients

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

November 21, 2025

Vol.51 No.43

By Claire Marie Porter and Sara Willa Ernst

Clinical Roundup

Targeted drug could benefit pediatric and young adult patients with invasive soft tissue cancer

A collaborative research team, led by scientists at VCU Massey Comprehensive Cancer Center and Huntsman Cancer Institute at the University of Utah, has identified a targeted drug that could effectively treat an aggressive soft tissue cancer that occurs most often in pediatric and young adult patients.

November 21, 2025

Vol.51 No.43

In Brief

James Hu named associate director of Sarcoma Program at Cedars-Sinai Cancer

James S. Hu was named associate director of the Sarcoma Program at Cedars-Sinai Cancer.

November 07, 2025

Vol.51 No.41

Clinical Roundup

Ozekibart improves PFS in chondrosarcoma, registrational phase II trial shows

Positive topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma were recently reported.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Drugs approved for pain also reduce bone cancer growth, Hopkins-led pre-clinical study finds

Federally funded research in mice showed that neurons regulate osteosarcoma progression, suggesting that inhibiting nerve signaling might improve patient outcomes.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Genetic “Trojan horse” selectively kills cancer cells linked to Kaposi’s sarcoma, UC Davis study shows

In a preclinical study, UC Davis Comprehensive Cancer Center scientists developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, with minimal side effects.

October 03, 2025

Vol.51 No.36

Phase III Eribulin Trial Boosts OS in Liposarcoma Patients

YOU MAY BE INTERESTED IN

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

Targeted drug could benefit pediatric and young adult patients with invasive soft tissue cancer

James Hu named associate director of Sarcoma Program at Cedars-Sinai Cancer

Ozekibart improves PFS in chondrosarcoma, registrational phase II trial shows

Drugs approved for pain also reduce bone cancer growth, Hopkins-led pre-clinical study finds

Genetic “Trojan horse” selectively kills cancer cells linked to Kaposi’s sarcoma, UC Davis study shows

Renew today!

Subscriber content

Never miss an issue!

Login

Phase III Eribulin Trial Boosts OS in Liposarcoma Patients

YOU MAY BE INTERESTED IN

Oncofertility coverage mandates expand to 21 states and DC as political momentum buildsGaps persist as patients face harrowing decisions and huge copays

Targeted drug could benefit pediatric and young adult patients with invasive soft tissue cancer

James Hu named associate director of Sarcoma Program at Cedars-Sinai Cancer

Ozekibart improves PFS in chondrosarcoma, registrational phase II trial shows

Drugs approved for pain also reduce bone cancer growth, Hopkins-led pre-clinical study finds

Genetic “Trojan horse” selectively kills cancer cells linked to Kaposi’s sarcoma, UC Davis study shows

Never miss an issue!

Login

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays